Business Standard

Pfizer concludes Rs 110 crore deal with Piramal Enterprises

Pfizer shares on Monday ended at Rs 1,930.40 apiece on the BSE, down 1.66% from previous close

Photo courtesy: Reuters

Photo courtesy: Reuters

Press Trust of India New Delhi
Drug maker Pfizer on Monday said it has completed the process of transferring four products to Mumbai-based Piramal Enterprises after getting necessary regulatory approvals.

"Post completion of requisite formalities and receipt of necessary regulatory approvals for the transaction, the company has concluded the transaction. Accordingly, the aforementioned products stand transferred to Piramal Enterprises," Pfizer said in a regulatory filing.

In May this year, Ajay Piramal-led Piramal Enterprises had entered into an agreement to acquire four brands from Pfizer for a consideration of Rs 110 crore.

The acquisition includes brands Ferradol, Neko, Sloan's and Waterbury's compound. The agreement also includes the trademark rights for Ferradol and Waterbury's Compound in Bangladesh and Sri Lanka.
 

Pfizer shares on Monday ended at Rs 1,930.40 apiece on the BSE, down 1.66 per cent from previous close.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 26 2016 | 4:48 PM IST

Explore News